Twist Bioscience’s (TWST) “Buy” Rating Reaffirmed at TD Cowen

TD Cowen reiterated their buy rating on shares of Twist Bioscience (NASDAQ:TWST) in a research note published on Tuesday,Benzinga reports. TD Cowen currently has a $58.00 price target on the stock.

Several other research firms have also commented on TWST. Robert W. Baird lifted their price target on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Scotiabank lifted their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Finally, Barclays cut their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $51.00.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $46.34 on Tuesday. The stock’s fifty day moving average is $43.78 and its two-hundred day moving average is $46.18. The firm has a market capitalization of $2.75 billion, a P/E ratio of -13.02 and a beta of 1.78. Twist Bioscience has a fifty-two week low of $23.07 and a fifty-two week high of $60.90.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 1,507 shares of Twist Bioscience stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the transaction, the insider now directly owns 91,163 shares of the company’s stock, valued at $4,375,824. The trade was a 1.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now directly owns 45,620 shares of the company’s stock, valued at approximately $2,034,652. This represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock valued at $4,391,151 in the last three months. 3.92% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. American International Group Inc. grew its position in shares of Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after buying an additional 213 shares in the last quarter. Caprock Group LLC grew its position in shares of Twist Bioscience by 2.9% during the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after buying an additional 220 shares in the last quarter. Signaturefd LLC lifted its stake in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the last quarter. Arizona State Retirement System lifted its stake in Twist Bioscience by 1.9% during the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after purchasing an additional 308 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Twist Bioscience by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after purchasing an additional 312 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.